Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
  • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/67—Vitamins
  • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations

Definitions

• the present invention relates to a personal care composition
• a personal care composition comprising carboxymethyl cysteine compound and retinoid, wherein the weight ratio of carboxymethyl cysteine compound to retinoid is 1:1.6 to 25:1. It was unexpectedly found that the expression of collagen type I alpha I chain was significantly enhanced by such composition.
• the skin is a primary barrier of the human body. It protects the organs in the body from external stimulations. It is subject to intrinsic aging and extrinsic aging. Skin aging is a complex process, and alterations in human skin due to aging have distinct characteristics as compared to other organs. Characteristics of intrinsic or chronological skin aging include dryness, visible free lines and wrinkles, uneven skin pigmentation, loss of elasticity and skin sagging. Extrinsic factors including exposure to sunlight, pollutants and cigarette smoke can accelerate the skin aging process, especially on the face.
• One of the most efficient ways for providing the effect of anti-aging is to promote the production of collagen. Upregulating the expression of collagen synthesizing genes typically leads to an increase in collagen production.
• the present invention is directed to a method of providing the skin benefits selected from the group consisting of enhancing collagen production in the skin, improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging and upregulating the expression of collagen synthesizing gene comprising a step of topically applying to the skin the composition of the composition of the present invention.
• the present invention is directed to use of the composition of the present invention for providing the skin benefits selected from the group consisting of enhancing collagen production in the skin, improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging and upregulating the expression of collagen synthesizing gene.
• the carboxymethyl cysteine compound refers to compound selected from carboxymethyl cysteine, salt of carboxymethyl cysteine, ester of carboxymethyl cysteine, amide of carboxymethyl cysteine or a mixture thereof.
• the carboxymethyl cysteine compound comprises carboxymethyl cysteine, ester of carboxymethyl cysteine, and/or salt of carboxymethyl cysteine.
• the carboxymethyl cysteine compound comprises carboxymethyl cysteine, and/or salt of carboxymethyl cysteine.
• carboxymethyl cysteine compound comprises salt of carboxymethyl cysteine.
• the carboxymethyl cysteine compound comprises lysine carboxymethyl cysteinate and most preferably, the carboxymethyl cysteine compound is lysine carboxymethyl cysteinate.
• the carboxymethyl cysteine compound is present in amount of at least 0.00001%, more preferably at least 0.0001 %, even more preferably at least 0.001 %, still even more preferably at least 0.01%, and most preferably at least 0.1 % by weight of the composition.
• the carboxymethyl cysteine compound is present in amount of no greater than 10%, more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1 %, and most preferably no greater than 0.5% by weight of the composition.
• the lysine carboxymethyl cysteinate is present in amount of no greater than 10%, more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1 %, and most preferably no greater than 0.5% by weight of the composition.
• the lysine carboxymethyl cysteinate is present in amount of at least 0.00001%, more preferably at least 0.0001 %, even more preferably at least 0.001%, still even more preferably at least 0.01 %, and most preferably at least 0.1% by weight of the composition.
• retinol includes the following isomers of retinol: all-trans-retinol, 13-cis-retinol, 11 -cis- retinol, 9-cis-retinol, 3,4-didehydro-retinol, 3, 4-didehydro-13-cis-retinol; 3, 4-didehydro- 11 -cis- retinol; 3,4-didehydro-9-cis-retinol.
• Preferred isomers are all-trans-retinol, 13-cis-retinol, 3,4- didehydro-retinol, 9-cis-retinol.
• Most preferred retinol is all-trans-retinol, due to its wide commercial availability.
• Retinyl ester is an ester of retinol.
• the term “retinol” has been defined above.
• Retinyl esters suitable for use in the present invention are preferably C1-C30 esters of retinol, more preferably C2-C20 esters of retinol, and most preferably C2, C3, and C esters of retinol.
• retinyl esters include but are not limited to: retinyl palmitate, retinyl formate, retinyl acetate, retinyl propionate, retinyl butyrate, retinyl valerate, retinyl isovalerate, retinyl hexanoate, retinyl heptanoate, retinyl octanoate, retinyl nonanoate, retinyl decanoate, retinyl undecanoate, retinyl laurate, retinyl tridecanoate, retinyl myristate, retinyl pentadecanoate, retinyl heptadecanoate, retinyl stearate, retinyl isostearate, retinyl nonadecanoate, retinyl arachidonate, retinyl behenate, retin
• Particularly preferred retinoid is selected from all-trans-retinol, retinyl palmitate, retinyl acetate, retinyl propionate, or a mixture thereof. More preferably the retinoid is selected from retinyl palmitate, retinyl propionate, or a mixture thereof. Even more preferably the retinoid is retinyl propionate.
• the total amount of retinyl palmitate and retinyl propionate in the composition is preferably in the range of 0.00001 to 10%, more preferably from 0.0001 to 8%, even more preferably from 0.001 to 5%, still even more preferably from 0.02 to 2%, most preferably from 0.1 to 0.6% by weight of the total amount of the composition.
• the amount of retinyl propionate in the composition is preferably in the range of 0.00001 to 10%, more preferably from 0.0001 to 8%, even more preferably from 0.001 to 5%, still even more preferably from 0.02 to 2%, most preferably from 0.1 to 0.6% by weight of the total amount of the composition.
• the weight ratio of the carboxymethyl cysteine compound to the retinoid is 1 :1.6 to 20: 1 , more preferably 1 : 1.6 to 10: 1 , even more preferably, still even more preferably 1 : 1.5 to 3: 1 and most preferably 1 :1.3 to 2:1.
• the weight ratio of the lysine carboxymethyl cysteinate to the retinoid is 1 :1.6 to 20:1 , more preferably 1:1.6 to 10:1 , even more preferably, still even more preferably 1 :1.5 to 3:1 and most preferably 1 :1.3 to 2:1.
• the weight ratio of the carboxymethyl cysteine compound to the total amount of retinol and retinyl ester in the composition is 1 : 1.6 to 20: 1 , more preferably 1 : 1.6 to 10: 1 , even more preferably, still even more preferably 1 :1.5 to 3:1 and most preferably 1 :1.3 to 2:1.
• the weight ratio of lysine carboxymethyl cysteinate to total amount of retinyl propionate and retinyl palmitate in the composition is 1 :1.6 to 20: 1 , more preferably 1 : 1.6 to 10: 1 , even more preferably, still even more preferably 1 : 1.5 to 3: 1 and most preferably 1 :1.3 to 2:1.
• the weight ratio of lysine carboxymethyl cysteinate to retinyl propionate in the composition is 1 :1.6 to 20:1, more preferably 1 :1.6 to 10:1 , even more preferably, still even more preferably 1 :1.5 to 3:1 and most preferably 1 :1.3 to 2:1.
• the molar ratio of the lysine carboxymethyl cysteinate to the retinoid is 1 :1.6 to 20:1, more preferably 1 :1.6 to 10:1, even more preferably, still even more preferably 1 :1.5 to 3:1 and most preferably 1 :1.3 to 2:1.
• the molar ratio of the carboxymethyl cysteine compound to the total amount of retinol and retinyl ester in the composition is 1 :1.6 to 20:1 , more preferably 1 :1.6 to 10:1 , even more preferably, still even more preferably 1:1.5 to 3:1 and most preferably 1 :1.3 to 2:1.
• the molar ratio of lysine carboxymethyl cysteinate to total amount of retinyl propionate and retinyl palmitate in the composition is 1 :1.6 to 20:1 , more preferably 1:1.6 to 10:1 , even more preferably, still even more preferably 1:1.5 to 3:1 and most preferably 1 :1.3 to 2:1.
• the molar ratio of lysine carboxymethyl cysteinate to retinyl propionate in the composition is 1 :1.6 to 20:1, more preferably 1:1.6 to 10:1 , even more preferably, still even more preferably 1:1.5 to 3:1 and most preferably 1 :1.3 to 2:1.
• the composition may optionally comprise whitening pigment.
• Whitening pigments are typically particles of high refractive index materials.
• the whitening pigment may have a refractive index of greater than 1.3, more preferably greater than 1.8 and most preferably from 2.0 to 2.7.
• Examples of such whitening pigment are those comprising bismuth oxy-chloride, boron nitride, barium sulfate, mica, silica, titanium dioxide, zirconium oxide, aluminium oxide, zinc oxide or combinations thereof.
• More preferred whitening pigment are particles comprising titanium dioxide, zinc oxide, zirconium oxide, mica, iron oxide or a combination thereof.
• Even more preferred whitening pigment are particles comprising zinc oxide, zirconium oxide, titanium dioxide or a combination thereof as these materials have especially high refractive index.
• the whitening pigment is selected from titanium dioxide, zinc oxide or a mixture thereof and most preferred whitening pigment is titanium dioxide.
• the average diameter of whitening pigment is typical from 15 nm to 1 micron, more preferably from 35 nm to 800 nm, even more preferably from 50 nm to 500 nm and still even more preferably from 100 to 300 nm.
• Amount of whitening pigment may be 0.1 to 15%, preferably 0.5 to 5% by weight of the composition.
• the composition comprises a glutamate source selected from the group consisting of glutamine, glutamine ester, glutamic acid, pyroglutamic acid, salts, and mixtures thereof. More preferably, the composition comprises pyroglutamic acid and/or salt of pyroglutamic acid. Even more preferably, the composition comprises sodium salt of pyroglutamic acid.
• the glutamate source is present in amount of 0.0001 to 10% by weight of the composition, more preferably 0.001 to 6%, even more preferably 0.01 to 3% by weight of the composition.
• the composition comprises polyhydric alcohol.
• Polyhydric alcohols may be selected from group of glycerin, propylyene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1 ,3-butylene glycol, isoprene glycol, ethoxylated glycerol, propoxylated glycerol or a mixture thereof.
• Most preferred polyhydric alcohol is glycerol known also as glycerin.
• the amount of polyhydric alcohol may range anywhere from 0.1 to 20%, preferably 0.5 to 15% and more preferably 2 and 10% by weight of the composition.
• Illustrative triglycerides but not limiting are sunflower seed oil, cotton oil, canola oil, soybean oil, castor oil, borage oil, olive oil, shea butter, jojoba oil and mixtures thereof. Mono- and di- glycerides may also be useful. Particularly preferable are glyceryl monostearate and glyceryl distearate.
• the composition comprises moisturizing agents.
• moisturizing agents includes, petrolatum, aquaporin manipulating actives, oat kernel flour, substituted urea like hydroxyethyl urea, hyaluronic acid and/or its precursor N-acetyl glucosamine, hyaluronic acid and/or its precursor N-acetyl glucosamine, or a mixture thereof.
• compositions may include thickeners. These may be selected from cellulosics, natural gums and acrylic polymers but not limited by this thickening agent types.
• cellulosics sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and combinations thereof.
• Suitable gums include xanthan, pectin, karaya, agar, alginate gums and combinations thereof.
• acrylic thickeners are homopolymers and copolymers of acrylic and methacrylic acids including carbomers such as Carbopol 1382, Carbopol 982, llltrez, Aqua SF-1 and Aqua SF-2 available from the Lubrizol Corporation.
• Amounts of thickener may range from 0.01 to 3% by weight of the active polymer (outside of solvent or water) in the compositions.
• compositions of the invention may further include 0.5 to 10% by weight of sequestering agents, such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures; opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene/Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.
• sequestering agents such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures
• opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene/Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.
• the composition may comprise water in amount of 10 to 96% by weight of the composition, more preferably from 25 to 92%, even more preferably from 42 to 88%, most preferably from 55 to 82% by weight of the composition.
• the composition has a viscosity of at least 10 mPa s, more preferably in the range 30 to 10000 mPa s, even more preferably 50 to 5000 mPa s, and most preferably 100 to 2000 mPa s, when measured at 20 degrees C at a relatively high shear rate of about 20 s’ 1 .
• the composition is an emulsion, more preferably an oil-in-water emulsion.
• the composition is a fluid liquid at 25 °C and atmospheric pressure.
• the personal care composition is a skin care composition.
• Skin care composition refers to a composition suitable for topical application to human skin, including leave-on and wash-off products but preferably leave-on compositions.
• leave-on as used with reference to compositions herein means a composition that is applied to or rubbed on the skin, and left thereon.
• wash-off as used with reference to compositions herein means a skin cleanser that is applied to or rubbed on the skin and rinsed off substantially immediately subsequent to application.
• skin as used herein includes the skin on the face, neck, chest, abdomen, back, arms, under arms, hands, and legs.
• skin means includes the skin on the face and under arms, more preferably skin means skin on the face other than lips and eyelids.
• the composition is particularly preferably a moisturizer rather than a make-up product.
• the composition is a topical composition.
• the composition may be in the form of cream, lotion, ointment, solution, suspension, emulsion, paste, gel, powder, powder foundation, emulsion foundation, wax foundation, or spray. More preferably, the composition may be formulated in the form of cream, lotion, ointment, emulsion, gel, or a spray.
• the use is non-therapeutic.
• the method is non-therapeutic.
• non-therapeutic typically means for cosmetic purposes and not curative or therapeutic purposes.
• the composition is capable of upregulating the expression of collagen type I alpha I chain (COL1A1) gene by at least 1.45 fold change, more preferably 1.55 to 5 and most preferably 1.75 to 3.5 and most preferably 1.75 to 2.5 fold change, typically in comparison to personal care composition comprising neither carboxymethyl cysteine compound nor retinoid.
• This Example demonstrates the synergistic anti-aging effect by combining lysine carboxymethyl cysteinate and retinyl propionate within a specific ratio.
• NHDF normal human dermal fibroblasts
• Biocell, Xi’an, China, Lot: Fb20081902 The normal human dermal fibroblasts (NHDF) (Biocell, Xi’an, China, Lot: Fb20081902) were incubated in medium together with or without actives for 48 hours. After incubation, the total RNA for each NHDF was extracted using RNAex Pro reagent (Accurate Biotechnology, Cat: AG21102) according to manufacturer’s protocol.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Dermatology (AREA)
• Cosmetics (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=88466731

Family Applications (1)

Country Status (5)

Family Cites Families (4)

• 2023
  • 2023-10-16 CN CN202380078265.0A patent/CN120282768A/zh active Pending
  • 2023-10-16 JP JP2025526431A patent/JP2025535578A/ja active Pending
  • 2023-10-16 WO PCT/EP2023/078588 patent/WO2024099690A1/en not_active Ceased
  • 2023-10-16 EP EP23790591.4A patent/EP4615404A1/de active Pending
• 2025
  • 2025-05-08 MX MX2025005414A patent/MX2025005414A/es unknown

Also Published As

Similar Documents

Legal Events